Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer

  • Authors:
    • Pilar Iniesta
    • Alberto Morán
    • Carmen De Juan
    • Ana Gómez
    • Florentino Hernando
    • Cristina García-Aranda
    • Cristina Frías
    • Antonio Díaz-López
    • Francisco-Javier Rodríguez-Jiménez
    • Jose-Luis Balibrea
    • Manuel Benito
  • View Affiliations

  • Published online on: January 1, 2007     https://doi.org/10.3892/or.17.1.217
  • Pages: 217-223
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Our main aim consists of investigating the clinical usefulness of gelatinases and their tissue inhibitors in non-small cell lung cancer (NSCLC). Thus, we have analysed in 111 NSCLCs, levels and activity of MMP-2, MMP-9, TIMP-1 and TIMP-2, by Enzymoimmunoassay and Gelatine zymography, respectively. Our data revealed higher MMP-2 net activity in the NSCLC population analyzed in this study, this parameter showing a significant association with the TNM stage of tumours (P=0.002). Moreover, MMP-9 levels were significantly associated with poor clinical evolution of patients (P=0.02). Also, disease-free survival time was higher for patients whose tumours showed TIMP-1 increased levels (P=0.04). Of interest, Cox multivariate analysis revealed that TIMP-1 levels can be considered as an independent prognostic factor in NSCLC. Relative Risk (RR) to tumour relapse was more than two times lower for patients showing high TIMP-1 levels (RR=0.420, P=0.041). Therefore, according to our results, we conclude that MMP-9 and TIMP-1 levels of synthesis could be useful for the selection of patients with potentially unfavourable clinical evolution in order to establish adjuvant therapy protocols. Among these parameters, TIMP-1 level evaluation emerges as the main factor to predict the clinical outcome of patients.

Related Articles

Journal Cover

January 2007
Volume 17 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Iniesta P, Morán A, De Juan C, Gómez A, Hernando F, García-Aranda C, Frías C, Díaz-López A, Rodríguez-Jiménez F, Balibrea J, Balibrea J, et al: Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep 17: 217-223, 2007
APA
Iniesta, P., Morán, A., De Juan, C., Gómez, A., Hernando, F., García-Aranda, C. ... Benito, M. (2007). Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncology Reports, 17, 217-223. https://doi.org/10.3892/or.17.1.217
MLA
Iniesta, P., Morán, A., De Juan, C., Gómez, A., Hernando, F., García-Aranda, C., Frías, C., Díaz-López, A., Rodríguez-Jiménez, F., Balibrea, J., Benito, M."Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer". Oncology Reports 17.1 (2007): 217-223.
Chicago
Iniesta, P., Morán, A., De Juan, C., Gómez, A., Hernando, F., García-Aranda, C., Frías, C., Díaz-López, A., Rodríguez-Jiménez, F., Balibrea, J., Benito, M."Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer". Oncology Reports 17, no. 1 (2007): 217-223. https://doi.org/10.3892/or.17.1.217